Merle Ferguson insider trades: Bioforce Nanosciences Holdings (BFNH) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Merle reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Apr 22, 2026 | BFNH | ↓ Sell | 26,700,000 | $0.01 | $401K | Direct | Sep 2, 2026 (133d) |
| Oct 2, 2023 | GRHI | ↓ Sell | 199,709,443 | $0.00 | $519K | Direct | Oct 4, 2023 (2d) |
| Apr 11, 2023 | BRVO | ↓ Sell | 30,000,000 | $0.02 | $600K | Direct | Apr 12, 2023 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Merle Ferguson's insider trades
Merle Ferguson is a director at Bioforce Nanosciences Holdings (BFNH). Since Apr 11, 2023, Merle has reported no open-market purchases and 3 sales worth $1.5M on SEC Form 4. In the last 12 months: 1 sale ($401K).
Their filings also include gifts (7 filings), grants and awards (4 filings), option exercises (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BFNH insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.